In the realm of medical breakthroughs, understanding patient experiences is paramount. In this spirit, the Save Your Skin Foundation embarked on a pioneering initiative, delving into the world of melanoma treatment. The survey, titled “The Patient Experience of Nivolumab + Relatlimab (Opdualag™),” crafted meticulously by the foundation, was designed to fathom the depths of Opdualag™ as a treatment for adult cutaneous melanoma in stage III unresectable or stage IV melanoma.
Save Your Skin Foundation developed this survey to gather patient experiences regarding the use of Opdualag™ as a treatment for adult cutaneous melanoma in stage III unresectable or stage IV melanoma. The survey was open to everyone who has received a treatment for melanoma, regardless of stage and experience with Opdualag™; however, data logic has been applied to ensure that only applicable participants answer the questions about Opdualag™. This information was used for Save Your Skin Foundation to prepare submissions for access to Opdualag™ to the Canadian Agency for Drugs and Technologies in Health (CADTH) and Institut national d’excellence en santé et en services sociaux (INESSS).
Two versions of the survey were open from July 3-July 15, 2023, one in English and one in French. Data from both of the surveys was combined for the aforementioned CADTH and INESSS submissions. For this presentation, visual representations of the English results will be accompanied by description of the French data for each question.
